Commonwealth Equity Services, LLC Vertex Pharmaceuticals Inc Transaction History

Commonwealth Equity Services, LLC

$66 Billion
Q3 2024

A detailed history of Commonwealth Equity Services, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 63,427 shares of VRTX stock, worth $25.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

63,427

Previous 85,575 25.88%

Holding current value

$25.9 Million

Previous $40.1 Million 26.46%

% of portfolio

0.04%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$460.0 - $505.78 $10.2 Million - $11.2 Million	-22,148 Reduced 25.88%	63,427 $29.5 Million
Q2 2024 Jul 31, 2024	BUY	$392.81 - $485.53 $2.5 Million - $3.09 Million	6,368 Added 8.04%	85,575 $40.1 Million
Q1 2024 Apr 29, 2024	BUY	$407.69 - $446.08 $1.9 Million - $2.08 Million	4,662 Added 6.25%	79,207 $33.1 Million
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $1.92 Million - $2.3 Million	5,598 Added 8.12%	74,545 $30.3 Million
Q3 2023 Oct 23, 2023	SELL	$338.18 - $362.46 $198,849 - $213,126	-588 Reduced 0.85%	68,947 $24 Million
Q2 2023 Aug 10, 2023	BUY	$314.42 - $351.91 $699,584 - $782,999	2,225 Added 3.31%	69,535 $24.5 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $287,478 - $327,946	1,015 Added 1.53%	67,310 $21.2 Million
Q4 2022 Feb 07, 2023	BUY	$285.76 - $321.48 $854,993 - $961,868	2,992 Added 4.73%	66,295 $19.1 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $2.12 Million - $2.37 Million	-7,743 Reduced 10.9%	63,303 $18.3 Million
Q2 2022 Jul 19, 2022	BUY	$234.96 - $292.55 $48,401 - $60,265	206 Added 0.29%	71,046 $20 Million
Q1 2022 May 04, 2022	BUY	$221.42 - $260.97 $1.2 Million - $1.42 Million	5,437 Added 8.31%	70,840 $18.5 Million
Q4 2021 Jan 31, 2022	SELL	$177.01 - $223.45 $1.66 Million - $2.1 Million	-9,388 Reduced 12.55%	65,403 $14.4 Million
Q3 2021 Oct 29, 2021	BUY	$181.39 - $202.99 $1.78 Million - $1.99 Million	9,820 Added 15.11%	74,791 $13.6 Million
Q2 2021 Aug 11, 2021	BUY	$187.49 - $221.1 $2.34 Million - $2.76 Million	12,489 Added 23.8%	64,971 $13.1 Million
Q1 2021 May 04, 2021	SELL	$207.02 - $241.31 $1.44 Million - $1.68 Million	-6,957 Reduced 11.7%	52,482 $11.3 Million
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $2.88 Million - $3.83 Million	13,889 Added 30.49%	59,439 $14 Million
Q3 2020 Nov 05, 2020	BUY	$255.65 - $303.1 $1.52 Million - $1.8 Million	5,930 Added 14.97%	45,550 $12.4 Million
Q2 2020 Aug 12, 2020	BUY	$225.48 - $295.8 $4.44 Million - $5.82 Million	19,673 Added 98.63%	39,620 $11.5 Million
Q1 2020 May 11, 2020	BUY	$199.77 - $247.81 $478,049 - $593,009	2,393 Added 13.63%	19,947 $4.75 Million
Q4 2019 Feb 05, 2020	BUY	$166.71 - $223.91 $389,934 - $523,725	2,339 Added 15.37%	17,554 $3.84 Million
Q3 2019 Oct 30, 2019	SELL	$166.23 - $187.09 $122,179 - $137,511	-735 Reduced 4.61%	15,215 $2.58 Million
Q2 2019 Jul 19, 2019	SELL	$164.61 - $190.37 $60,741 - $70,246	-369 Reduced 2.26%	15,950 $2.92 Million
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $118,049 - $140,378	721 Added 4.62%	16,319 $3 Million
Q4 2018 Feb 11, 2019	BUY	$151.91 - $192.21 $22,786 - $28,831	150 Added 0.97%	15,598 $2.58 Million
Q3 2018 Nov 06, 2018	BUY	$167.73 - $192.74 $836,972 - $961,772	4,990 Added 47.71%	15,448 $2.98 Million
Q2 2018 Jul 31, 2018	BUY	$145.72 - $169.96 $86,120 - $100,446	591 Added 5.99%	10,458 $1.78 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $91,414 - $106,809	603 Added 6.51%	9,867 $1.61 Million
Q4 2017 Feb 12, 2018	BUY	$137.28 - $155.55 $1.27 Million - $1.44 Million	9,264	9,264 $1.39 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Account

Commonwealth Equity Services, LLC Vertex Pharmaceuticals Inc Transaction History